• Thursday, December 14, 2023 @ 12:00 am

The shareholders of Athebio AG, a biotech company enabling drug developers to create superior targeted therapeutics of advanced efficacy and safety by harnessing its proprietary “plug & play” Athebody DARPin technology platform, recently elected Dr. Jens Hennecke, PhD, as new member of the Board of Directors.

Dr. Hennecke brings his wealth of experience and expertise in the biopharmaceutical industry to Athebio. He also serves as Chief Business Officer at SOTIO Biotech.

Before joining SOTIO, he operated his own business consulting firm, offering valuable insights to European biotech companies, and also served as a non-executive Director on the Board of NBE-Therapeutics AG in Basel, Switzerland.

Dr. Hennecke's notable career includes his 10-year tenure at Micromet, Inc., where he served the role of Senior Vice President of Business Development. During this time, he successfully closed several corporate deals with pharmaceutical companies, and played a key role in the company's acquisition by Amgen in 2012.

Educationally, he holds a diploma in biology from the University of Göttingen, Germany, and earned his Ph.D. from ETH Zürich, Switzerland. His postdoctoral research at Harvard University further enriches his background and deep understanding of the intricacies of translational Science, making him a valuable addition to the leadership team at Athebio AG.

Patrik Forrer, CEO, commented: “We are delighted and honored to welcome Jens to Athebio’s Board! With his broad and deep scientific and business background and his extensive experience in deal making, he will continue to bring valuable experience and know-how to Athebio. As we progress towards establishing Athebody DARPins as “plug & play” building blocks for innovative drugs and move forward with our partnerships, Jens will play an instrumental role in shaping the future for Athebio and our partners.”

Dr. Hennecke added: “Knowing the DARPin technology since its beginnings at the University of Zurich, I believe Athebio's proprietary Athebody DARPin platform holds tremendous potential to empower drug developers in creating industry-leading therapeutics. I am looking forward to contributing to shaping Athebio's strategy for introducing this promising technology to innovation leaders worldwide.“

You may also be interested in